Clinical trials: Respiratory Exacerbation
Asthma
Long Term Special Drug Use Investigation of Mepolizumab
This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC).
- Trial name
- NCT03028480
- Testing
- NUCALA Injection
- Volunteers
- 1,061 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297115
- Testing
- Roflumilast
- Where
- 287 sites in United States, Canada and 6 more
- Volunteers
- 1,568 people
- Sponsor
- AstraZeneca
Pneumonia, Bronchiolitis
Diagnosing Respiratory Disease in Children Using Cough Sounds 2
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood acute respiratory disease, including pneumonia, bronchiolitis, asthma/reactive airways disease…
- Conditions
- Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup
- Trial name
- SMARTCOUGH-C-2 (NCT03392363)
- Testing
- Recordings of Infants and Children's Cough Sounds
- Where
- 3 sites in United States
- Volunteers
- 1,470 people
- Sponsor
- ResApp Health Limited
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.
- Trial name
- TERRANOVA (NCT02155660)
- Testing
- Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 2,255 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to evaluate the efficacy of Helium/Oxygen (He/O2) 78%/22% compared to a conventional Air/O2 mixture in reducing endotracheal intubation rate and mortality in patients with severe hypercapnic…
- Trial name
- ECHO/ICU (NCT01155310)
- Testing
- Helium/Oxygen 78%/22%, Air/Oxygen
- Where
- 16 sites in Belgium, France and 4 more
- Volunteers
- 446 people
- Sponsor
- Air Liquide Santé International
Idiopathic Pulmonary Fibrosis
Ongoing Monitoring of Vital Signs in Patients With Idiopathic Pulmonary Fibrosis Before and After Acute Exacerbation.
The aim of this study is to assess the feasibility of early detection of acute exacerbations of idiopathic pulmonary fibrosis by the remote monitoring of vital signs.
- Trial name
- REACT (NCT06445686)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Biosency
COPD
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.
- Trial name
- NCT01645800
- Testing
- Lysozyme hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 408 people
- Sponsor
- Eisai Co., Ltd.
Acute Exacerbation of COPD
Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD
This study evaluates the safety and efficacy of using the Hemolung RAS to provide low-flow extracorporeal carbon dioxide removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients who require…
- Trial name
- VENT-AVOID (NCT03255057)
- Testing
- Hemolung Respiratory Assist System, Invasive mechanical ventilation
- Where
- 32 sites in United States
- Volunteers
- 113 people
- Sponsor
- Alung Technologies
Asthma
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma…
- Trial name
- DREAM (NCT01000506)
- Testing
- Mepolizumab 750, Mepolizumab 250, Mepolizumab 75
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 621 people
- Sponsor
- GlaxoSmithKline
Chronic Bronchitis
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial.
- Trial name
- NCT00255983
- Testing
- Faropenem medoxomil
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Replidyne
Chronic Bronchitis, Disease Exacerbation
VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of…
- Trial name
- VICTOR (NCT00876577)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- China
- Volunteers
- 1,206 people
- Sponsor
- Bayer
COPD
This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiology Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Korea
This study is designed as a multicenter, prospective and retrospective and descriptive epidemiology study. This study is planned to evaluate 2 years of exacerbation in COPD patients and to investigate correlation of COPD disease…
- Trial name
- EPOCH (NCT01419379)
- Where
- 14 sites in South Korea
- Volunteers
- 1,118 people
- Sponsor
- Takeda
Allergic Asthma
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model.
- Trial name
- NCT06592768
- Testing
- Briquilimab
- Where
- 6 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Jasper Therapeutics, Inc.
Non Cystic Fibrosis Bronchiectasis
Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.
The primary objective of the trial was to investigate the effect of the use of inhaled colistimethate sodium (CMS), administered twice a day (b.i.d.) via a specific nebulizer for 12 months, compared to placebo in subjects with…
- Trial name
- PROMIS-II (NCT03460704)
- Testing
- CMS
- Where
- 89 sites in United States, Argentina and 10 more
- Volunteers
- 287 people
- Sponsor
- Zambon SpA
Asthma
A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection
A study to investigate if inhaled Interferon beta-1a is safe and tolerated, and can prevent or reduce the severity of asthma attacks when administered to asthma patients at the onset of symptoms of common cold or influenza
- Trial name
- INEXAS (NCT02491684)
- Testing
- Interferon beta-1a Nebuliser solution 48 μg/mL
- Where
- 35 sites in Argentina, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Bronchitis, Chronic
A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis
This study compared the clinical efficacy and safety of azithromycin with that of amoxicillin-clavulanic acid, in patients between the ages of 35 and 75 years, presenting with an exacerbation of chronic bronchitis.
- Trial name
- NCT00649831
- Testing
- Amoxicillin/clavulinic acid, Azithromycin
- Where
- 31 sites in France
- Volunteers
- 250 people
- Sponsor
- Pfizer
COPD, COPD Exacerbation
Study of Physiological Signals During and After COPD Exacerbations
Background : Acute exacerbations of COPD (Chronic Obstructive Pulmonary Disease) are frequent events in the course of the disease and they can deteriorate the respiratory function of the patients, impact their quality of life and…
- Trial name
- DACRE (NCT04034901)
- Testing
- Monitoring of cardiorespiratory parameters with BORA Band
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Biosency
COPD Acute Exacerbation
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
- Trial name
- NCT06940154
- Testing
- Rademikibart in prefilled syringe
- Where
- 52 sites in United States, Argentina and 4 more
- Volunteers
- 159 people
- Sponsor
- Connect Biopharm LLC
Asthma
Study Of Asthma In Patients Of African Descent
This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests.
- Trial name
- NCT00102765
- Testing
- fluticasone propionate/salmeterol powder, fluticasone propionate powder
- Where
- 75 sites in United States
- Volunteers
- 479 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)
A real world study to determine the effectiveness of a patient support service to aid COPD patients in their self management.
- Trial name
- Me&MyCOPD (NCT02300090)
- Testing
- Test Group, Control Group
- Where
- 23 sites in United Kingdom
- Volunteers
- 161 people
- Sponsor
- AstraZeneca